Key result
Transcatheter aortic valve replacement is emerging as a potential alternative to surgical aortic valve replacement for patients with severe symptomatic aortic regurgitation and high surgical risk.
Why the study?
Does transcatheter aortic valve replacement serve as a viable alternative to surgical aortic valve replacement in patients with severe symptomatic native aortic regurgitation who are at high risk for surgery?
Does transcatheter aortic valve replacement serve as a viable alternative to surgical aortic valve replacement in patients with severe symptomatic native aortic regurgitation who are at high risk for surgery?
TAVR is highlighted as an emerging potential alternative to the gold-standard SAVR for the management of severe symptomatic aortic regurgitation in patients with surgical risks.
Aortic regurgitation (AR) is a common valvular heart disease with an estimated prevalence of 2-4% among patients aged > 65 years (1-2). Untreated AR is associated with left ventricular dysfunction, heart failure, and death (3). Surgical aortic valve replacement (SAVR) is considered the gold standard for the management of severe symptomatic AR (3,4). However, for patients with perceived or real risks associated with SAVR, transcatheter aortic valve replacement (TAVR) is emerging as a potential alternative.
No takes yet. Share an insight, caveat, or question.
Santiago A. Garcia (2026) conducted a review in Aortic regurgitation. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve replacement is emerging as a potential alternative to surgical aortic valve replacement for patients with severe symptomatic aortic regurgitation and high surgical risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: